Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO
about
Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease interventionEffect of redox modulating NRF2 activators on chronic kidney diseaseEmerging roles of Nrf2 signal in non-small cell lung cancerA generalizable platform for interrogating target- and signal-specific consequences of electrophilic modifications in redox-dependent cell signalingIn Situ Observation of Thiol Michael Addition to a Reversible Covalent Drug in a Crystalline Sponge.The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Chemical constituents from a Gynostemma laxum and their antioxidant and neuroprotective activities.Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatmentRTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteersProphylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasomeCancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.Non-electrophilic modulators of the canonical Keap1/Nrf2 pathwayPterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain.Andrographolide Activates Keap1/Nrf2/ARE/HO-1 Pathway in HT22 Cells and Suppresses Microglial Activation by Aβ42 through Nrf2-Related Inflammatory Response.Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.Structural basis of Keap1 interactions with Nrf2.Glycosylation of KEAP1 links nutrient sensing to redox stress signaling.Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells.Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells.CDDO and Its Role in Chronic Diseases.Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response.The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling.Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs.KEAP1 and Done? Targeting the NRF2 Pathway with Sulforaphane.C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape.Effects of 3-Bromo-4,5-dihydroisoxazole Derivatives on Nrf2 Activation and Heme Oxygenase-1 Expression
P2860
Q26778356-016681FA-B531-499C-B3F0-F9A9B2AEB9BCQ26827726-857B2D36-8311-4F79-87EE-769A1E3F6C08Q28078928-89AFCA5B-658E-4690-B3C6-BB609B513EE7Q28385286-6769475A-5E4B-4D31-A706-46BB7F60D588Q31057399-6145FAAD-81F8-4FEA-BB5E-A2FF1CB122DBQ33659621-E5FAA4CD-5503-47D5-9663-374E4112B982Q33721819-8133D4FD-C45F-4D73-874A-52C35FA486B6Q35118710-B95516FD-D962-4E80-AAE2-CD3DD17E6844Q35512908-0B1CE7F7-C69B-4362-8A9C-6E2A5A754934Q35690117-58C9330C-F52E-46E9-8D8D-C52033BE394DQ35694891-55B517C6-C700-484D-AA64-784B618E8DD4Q35753567-53C5F668-AF61-4DFE-9826-495B00641DDBQ36144939-521CB27A-0766-48AC-B22E-A78A20CD673BQ36277241-00E32CE2-455E-447F-86E3-17C14DB345A3Q36497820-1DDF39FC-D8E6-4B16-89F7-E9F6BEBDED59Q37714716-25B3254D-25F1-4E45-8719-E336044D8E31Q38289589-B20E094A-0474-4E29-B96C-2DFE84F70312Q38522152-22EBA530-2A00-4931-871D-7BC38A0B9EB6Q38664878-29656396-6352-4C27-A9CF-0A987F508EE4Q38712952-99DCCB00-F2EF-4B85-B659-451A0F5D7250Q38742679-F2061839-9B21-43EA-82E0-F44B5802FD4CQ38807055-9185538A-5C3A-45D9-A458-EDEED58D4932Q38822665-9C70F7B3-D4C6-43B6-91E4-053C5AA6BF70Q38837451-E476987C-6F37-456E-B999-C2A8AEC97C8FQ38889475-DD4791ED-C5FB-4F0B-A874-03C83A315699Q38920601-34753B44-C508-43F7-8F25-4C3BB60BE441Q39270529-F3BB219D-700E-4BBE-9315-6C5704209684Q39375357-C2ABDF59-CAAE-48DC-84AC-7353CCF359FAQ41634246-D7C65013-C721-4F55-AC7A-1A622CAF1CECQ41914517-67F4D8EE-BF36-4009-976A-30310EC16F51Q47903962-19D12743-4D6D-479E-A193-FDA88521897CQ48774191-AEB3B229-BD80-4AC4-8997-85088C5750EDQ49834826-1D0999D8-DFED-4899-A7CC-EC48C45D29DBQ55256229-A6964BEE-BF80-4782-8382-C371061A7EF7Q58569406-AD3DC4F4-4B4A-43F5-8B78-7F7C53A65F59
P2860
Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@ast
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@en
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@nl
type
label
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@ast
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@en
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@nl
prefLabel
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@ast
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@en
Structure of the BTB domain of ...... e triterpenoid antagonist CDDO
@nl
P2093
P2860
P1433
P1476
Structure of the BTB Domain of ...... e Triterpenoid Antagonist CDDO
@en
P2093
Anne Cleasby
Caroline Richardson
Hongwei Qi
James F Callahan
Jeffrey K Kerns
Nestor Concha
Pamela A Williams
Paris Ward
Philip J Day
P2860
P304
P356
10.1371/JOURNAL.PONE.0098896
P407
P50
P577
2014-01-01T00:00:00Z